BioLargo Inc subsidiary Clyra Medical's COVID-19-inactivating spray Clyraguard now available to the public

BioLargo Inc (OTCQB:BLGO) subsidiary Clyra Medical technologies announced Thursday that Clyraguard, a personal disinfectant spray designed to decontaminate masks and other PPE, is now available to the public at www.clyramedical.com. Clyraguard is a hospital-grade, Food and Drug Administration-registered germicide that can be easily applied on the go, the company said, without having to remove a mask. The spray has been proven to deliver 99.999% antimicrobial efficacy against viruses, bacteria and fungi.  Most importantly, Clyraguard has demonstrated complete inactivation of SARS-CoV-2, the virus that causes COVID-19, according to recent testing at the University of Texas Medical Branch at Galveston. READ: BioLargo's CupriDyne-based disinfectant kills the coronavirus in 10 minutes, study says Clyraguard is clear, colorless and odorless, as well as non-irritating, non-sensitizing and non-toxic, the company said. Available in 4 oz spray bottles, the disinfectant spray is small enough to fit in a pocket but still contains two months of supply with typical usage. Previously, this hospital-grade disinfectant was available only to healthcare professionals. The spray is based on Clyra Medical's advanced wound care technology, which itself previously received 510(k) clearance from the FDA. "We have taken our patent-pending copper-iodine complex technology used for advanced wound care and infection control and prevention and developed a consumer-oriented product to further safeguard against COVID-19," CEO Steve Harrison said in a statement. "Clyraguard is gentle and safe. Its eco-friendly ingredients are mineral-based, alcohol-free, non-toxic, non-irritating and non-sensitizing. Just two-to-three sprays, which you can apply over your mask while you are wearing it, affords an added layer of protection, sustaining activity against unwanted pathogens including the SARS-CoV-2 virus." Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com Follow him on Twitter @andrew_kessel